• Login
• Admin

Nguyen, Van Thu and Rivière, Philippe and Ripoll, Pierre and Barnier, Julien and Vuillemot, Romain and Ferrand, Gabriel and Cohen-Boulakia, Sarah and Ravaud, Philippe and Boutron, Isabelle and Alawadhi, Solaf and Amer-Yahia, Sihem and Ávila, Camila and Bafeta, Aïda and Baudry, Julia and Bollig, Claudia and Bonnet, Hillary and Boutron, Isabelle and Bouet, Marinette and Cabanac, Guillaume and Chaimani, Anna and Chavalarias, David and Chen, Yaolong and Chevance, Astrid and Cohen-Boulakia, Sarah and Coquery, Emmanuel and Conil, Francoise and Davidson, Mauricia and De Nale, Laura and Devane, Declan and Diard, Elise and Doreau, Bastien and Evrenoglou, Theodoros and Fabri, Alice and Feron, Gilles and Ferrand, Gabriel and Fezeu, Leopold and Fouet, Mathilde and El Chall, Lina Ghosn and Graña, Carolina and Grasselli, Giacomo and Grolleau, François and Hacid, Mohand-Said and Haddy, Loubna and Hansen, Camilla and Hohlfeld, Ameer and Hróbjartsson, Asbjørn and Julia, Chantal and Mavridis, Dimitris and Meerpohl, Joerg J. and Meyer, Brice and Naidoo, Nivantha and Thu, Van Nguyen and Oikonomidi, Theodora and Pienaar, Elizabeth and Quirke, Fiona and Rada, Gabriel and Ravaud, Philippe and Ripoll, Pierre and Riveros, Carolina and Rivière, Philippe and Sauvant, Marie and Schmucker, Christine and Toumani, Farouk and Tovey, David and Vuillemot, Romain and Xia, Jun and Yu, Xuan and Zoletic, Emina and Zweigenbaum, Pierre (2020) Research response to coronavirus disease 2019 needed better coordination and collaboration: a living mapping of registered trials. Journal of Clinical Epidemiology, 130 . pp. 107-116. ISSN 08954356

Preview

PDF - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader Available under Licence Creative Commons Attribution Non-commercial No Derivatives. Download (1MB) | Preview

Abstract

Objectives: Researchers worldwide are actively engaging in research activities to search for preventive and therapeutic interventions against coronavirus disease 2019 (COVID-19). Our aim was to describe the planning of randomized controlled trials (RCTs) in terms of timing related to the course of the COVID-19 epidemic and research question evaluated. Study Design and Setting: We performed a living mapping of RCTs registered in the WHO International Clinical Trials Registry Platform. We systematically search the platform every week for all RCTs evaluating preventive interventions and treatments for COVID-19 and created a publicly available interactive mapping tool at https://covid-nma.com to visualize all trials registered. Results: By August 12, 2020, 1,568 trials for COVID-19 were registered worldwide. Overall, the median ([Q1–Q3]; range) delay between the first case recorded in each country and the first RCT registered was 47 days ([33–67]; 15–163). For the 9 countries with the highest number of trials registered, most trials were registered after the peak of the epidemic (from 100% trials in Italy to 38% in the United States). Most trials evaluated treatments (1,333 trials; 85%); only 223 (14%) evaluated preventive strategies and 12 postacute period intervention. A total of 254 trials were planned to assess different regimens of hydroxychloroquine with an expected sample size of 110,883 patients. Conclusion: This living mapping analysis showed that COVID-19 trials have relatively small sample size with certain redundancy in research questions. Most trials were registered when the first peak of the pandemic has passed.

Actions (Archive Staff Only)

Edit View